Actualités

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The pharma giant is taking steps to expand its portfolio.

The blended fair value estimate for Hims & Hers Health has moved from US$24.31 to US$26.82 per share, a change of around 10% in the latest update. That shift reflects a mix of more constructive views tied to the Novo Nordisk partnership and new product optionality, set against ongoing concerns around margins, regulation and execution that keep analyst opinions divided. As you read on, you will see how these moving pieces shape the evolving story and what to watch next in the analyst...

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 11, 2026, Citi raised the firm’s price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $3.10 from $2.30 and maintained a Buy rating following the company’s Q1 2026 earnings report. On May 7, 2026, Lexicon Pharmaceuticals, Inc. […]

Novo Nordisk (NYSE:NVO) has entered a partnership with OpenAI to apply artificial intelligence across drug discovery, manufacturing, and supply chain operations. The company is preparing a global rollout of the oral Wegovy weight loss pill after its US launch. Recent trial data for semaglutide and pipeline drugs such as Amycretin and CagriSema indicate further progress in obesity and metabolic disease treatments. Novo Nordisk is drawing fresh attention as it pairs an AI push with a growing...

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index advancing 0.8% and the State

Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.

European stock markets closed higher Friday as the Stoxx Europe 600 rose 0.7%, Germany's DAX 40 clim

Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of their body weight over 80 weeks at the highest dose. The results from the TRIUMPH-1 trial, the...

Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5% and the actively trad

(Updates with Novo Nordisk's response in the fourth paragraph.) Novo Nordisk's (NVO) Ozempic and

The findings could broaden the long-term opportunity for obesity and diabetes treatments.

The launch follows Novo Nordisk’s failure to pay a C$250 patent maintenance fee in Canada.

Late-stage trial data strengthens Lilly's obesity drug pipeline.

Retatrutide helped patients lose up to 28.3% of body weight over 80 weeks.

Eli Lilly and Company (NYSE:LLY), featuring a net income margin of 34.99% and upside potential of 20.64%, secures a spot on our list of the best extremely profitable stocks to buy according to Wall Street analysts. The company reported net income of $20.64 billion for the recently completed fiscal year (FY25). That earnings strength was […]

Novo Nordisk presented new Phase 3 ESSENCE data on semaglutide’s liver safety and efficacy at EASL 2026. The update includes the first dedicated results in menopausal women and Japanese patients with MASH. Findings suggest a consistent hepatic safety profile across these historically underrepresented groups. Novo Nordisk (CPSE:NOVO B) is drawing fresh attention with these MASH data at a time when its share price stands at DKK288.4. The stock is up 11.8% over the past 30 days but remains...

Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.

European equities traded in the US as American depositary receipts were tracking marginally lower la

GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.

LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.

Eli Lilly’s investigational drug, retatrutide, delivered an average 80-week weight loss of 70 pounds at the highest dose.

Lilly said people on the next-generation weight loss medication across three different dosages achieved weight loss of 19% to 28%.

By Sriparna Roy May 21 (Reuters) - Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's

Demand for weight loss drugs may fuel growth for more than one player.

Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro at $8.66B (+125%) and Zepbound at $4.16B (+80%). CEO David Ricks told investors “2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue ... Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

LONDON/NEW YORK, May 21 (Reuters) - Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nine U. Prices for the lowest doses of both Novo's oral Wegovy and Lilly's Foundayo tend to be lower than for their injected obesity ‌medicines, and at par with those offered by pharmacies that mix the ingredients themselves and make compounded versions.

Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.